Pfizer Inc's subsidiary Hospira has secured an Indian patent for an improved process for the preparation of Cilastatin. Cilastatin is a chemical which acts with anti-biotic Imipenem for the treatment of infections in various body systems. Imipenem and Cilastatin are combined in a drug to make an anti-biotic. It is used to treat serious infections that are mild to moderate in severity, such as lower respiratory infection and heart valve infection.
The Imipenem-Clastatin intravenous drugs are marketed under the common brand name Primaxin. The patent application was originally filed by Chennai-based Orchid Chemicals & Pharmaceuticals in 2005. But, Orchid Pharma sold some of its business to Hospira in 2009, leading to the patent application getting transferred to the latter. Hospira was recently acquired by Pfizer.
Subscribe to PharmaTutor News Alerts by Email >>
